Brookline Capital Acquisition Corp

NASDAQ:BCAC   3:56:34 PM EDT
10.12
0.00 (-0.04%)
Exchange Changes, Mergers / Acquisitions, Equity Financing / Related

Apexigen, Brookline Capital Acquisition Corp Announce Business Combination Agreement To Create Publicly Listed Immuno-Oncology Company

Published: 03/18/2022 10:48 GMT
Brookline Capital Acquisition Corp (BCAC) - Apexigen and Brookline Capital Acquisition Corp.
Announce Business Combination Agreement to Create Publicly Listed Immuno-oncology Company.
Brookline Capital Acquisition Corp.
- Combined Company Expected to Be Listed on Nasdaq Under Ticker Symbol "apgn.
Brookline Capital Acquisition Corp.
- Upon Closing of Transaction, Brookline Capital Acquisition Corp.
Will Be Renamed Apexigen, Inc.brookline Capital Acquisition Corp.
- Combined Co Will Be Led by Xiaodong Yang, President and CEO of Apexigen.
Brookline Capital Acquisition - Deal Values Apexigen at $205 Million on Net-equity Basis, Net of Exercise Proceeds for Apexigen's Pre-closing Options, Warrants.
Brookline Capital Acquisition Corp.
- Co and Lincoln Park Have Entered Into a Committed Investment Agreement and Related Registration Rights Agreement.
Brookline Capital Acquisition - Under Agreement Combined Co to Have Right to Direct Lincoln Park to Buy Up to $50 Million of Common Stock Over 24-month Period.
Brookline Capital Acquisition Corp.
- Following Merger, Combined Co's Board Shall Consist of 7 Members, of Which Apexigen Will Select 6.